Eisai (company)
Native name | エーザイ株式会社 |
|---|---|
Romanized name | Ēzai kabushiki gaisha |
| Company type | Public KK |
| TYO: 4523 TOPIX Large 70 Component TOPIX 100 Component Nikkei 225 Component | |
| Industry | Pharmaceuticals |
| Founded | December 6, 1941 |
| Founder | Toyoji Naito |
| Headquarters | 4-6-10 Koishikawa, Bunkyo-ku, Tokyo 112-8088, Japan |
Key people | Haruo Naito (President and CEO) |
| Products | |
| Revenue | ¥ 741.8 billion (2023) |
| ¥ 53.4 billion (2023) | |
| ¥ 43.8 billion (2023) | |
| Total assets | ¥ 743.9 billion (2023) |
| Total equity | ¥ 430.2 billion (2023) |
| Owner | The Master Trust Bank of Japan (11.78%) Japan Trustee Services Bank (10.99%) Nippon Life (4.29%) |
Number of employees | 10,000 (2023) |
| Website | Official website |
| Footnotes / references | |
Eisai Co., Ltd. (Japanese: エーザイ株式会社, Hepburn: Ēzai Kabushiki-gaisha) is a Japanese pharmaceutical company headquartered in Tokyo, Japan. It has some 10,000 employees, among them about 1,500 in research. Eisai is listed on the Tokyo Stock Exchange and is a member of the Topix 100 and Nikkei 225 stock indices.